Etanercept is an inhibitor of the pro-inflammatory and immunoregulatory cytokine tumor necrosis factor-α (TNFα). It has been proved highly effective in the treatment of rheumatoid arthritis, psoriasis and ankylosing spondylitis, although several potentially severe side effects have been reported, including infections and allergic reactions. Recently, attention has been drawn to an increased risk of demyelinating diseases in patients treated with TNFα inhibitors [1] . Here, we present a case of a patient who developed an acute demyelinating spinal cord lesion while being treated with etanercept.
Our case highlights myelitis as a rare side-effect of etanercept that should prompt discontinuation of the drug and consideration of immunotherapy. It is well known that TNFα inhibitors can increase the number of exacerbations and gadolinium-enhancing lesions in patients with multiple sclerosis (MS) and they are accordingly contraindicated in patients with a history of a demyelinating disorder [2, 3] . More recently, peripheral and central demyelinating diseases have been reported in patients naïve of demyelinating events that were treated with TNFα inhibitors [1, 4] . Observed disorders ranged from Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP) to retrobulbar neuritis, demyelinating (MS-like) encephalitis and transverse myelitis. Symptoms partially or fully resolved in the majority of patients after discontinuation of TNFα inhibitors and glucocorticoid treatment [1, 4] . Arguments in favour of a true association between TNFα inhibition and occurrence of demyelination in our case include the temporal association between etanercept treatment and manifestation of symptoms and improvement of symptoms upon etanercept discontinuation. A causal link is moreover supported by the report of similar disorders after exposure to TNFα inhibitors and positive re-challenge phenomena described in several cases [4, 5] . Without rechallenge, our patient remained without neurological deficits after follow-up of 8 months. Previous studies furthermore suggest that inhibition of TNFα induces complex alterations of immune homeostasis that are not restricted to suppression of pro-inflammatory actions (effective in the treatment of rheumatic diseases) but may also include promotion of autoimmune mechanisms [4] . The latter is in line with observations of stimulation of autoantibody production induced by treatment with TNFα inhibitors [6] . In summary, these observations strongly suggest a causal role of TNFα inhibition in the pathogenesis of myelitis in our patient, although there is no definite proof without a positive re-challenge phenomenon.
Taken together, our report demonstrates a rare but important side effect of etanercept treatment. Clinicians thus need to consider demyelinating diseases as differential diagnosis in patients with TNFα inhibitor treatment that present with new neurological deficits. In these patients, a discontinuation of etanercept treatment and IV glucocorticoid treatment is warranted.
